

The New York Academy of Medicine

Financial Statements

December 31, 2021 and 2020

Independent Auditors' Report

Board of Trustees The New York Academy of Medicine

Opinion

We have audited the accompanying financial statements of The New York Academy of Medicine ("NYAM"), which comprise the statements of financial position as of December 31, 2021 and 2020, the related statements of activities, functional expenses and cash flows for the years then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of NYAM as of December 31, 2021 and 2020, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of NYAM and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about NYAM's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

Auditors' Responsibilities for the Audit of the Financial Statements (continued)

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of NYAM's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about NYAM's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

PKF O'Connor Davies, LLP

May 23, 2022

The New York Academy of Medicine

Statements of Financial Position

	December 31	
	2021	2020
ASSETS		
Cash and cash equivalents	\$ 149,952	\$ 635,437
Contributions and grants receivable, net	1,553,857	1,292,813
Accounts receivable	80,752	244,489
Prepaid expenses and other assets	43,638	36,389
Investments	73,115,689	68,211,374
Restricted investments	1,445,189	1,246,957
Property and equipment, net	7,211,771	7,488,140
Beneficial interest in perpetual trust	160,678	171,972
	<u>\$ 83,761,526</u>	<u>\$ 79,327,571</u>
 LIABILITIES AND NET ASSETS		
Liabilities		
Accounts payable and accrued expenses	\$ 807,006	\$ 745,778
Other payables	-	25,382
Grants payable	456,000	312,500
Deferred income	122,327	275,634
Deferred compensation	1,445,189	1,246,957
Total Liabilities	<u>2,830,522</u>	<u>2,606,251</u>
 Net Assets		
Without donor restrictions	<u>48,797,213</u>	<u>44,470,006</u>
With Donor Restrictions		
Time or purpose restricted	20,065,454	20,273,459
Investments held in perpetuity	12,068,337	11,977,855
Total With Donor Restrictions	<u>32,133,791</u>	<u>32,251,314</u>
Total Net Assets	<u>80,931,004</u>	<u>76,721,320</u>
	<u>\$ 83,761,526</u>	<u>\$ 79,327,571</u>

See notes to financial statements

The New York Academy of Medicine

Statements of Activities

	Year Ended December 31, 2021				Year Ended December 31, 2020			
	Without Donor Restrictions	With Donor Restrictions		Total	Without Donor Restrictions	With Donor Restrictions		Total
		Time or Purpose Restricted	Investments Held in Perpetuity			Time or Purpose Restricted	Investments Held in Perpetuity	
OPERATING ACTIVITIES								
Operating Support								
Grants and contributions	\$ 680,267	\$ 3,983,719	\$ -	\$ 4,663,986	\$ 929,271	\$ 3,533,239	\$ -	\$ 4,462,510
PPP loan forgiveness	1,442,947	-	-	1,442,947	1,568,262	-	-	1,568,262
Total Operating Support	2,123,214	3,983,719	-	6,106,933	2,497,533	3,533,239	-	6,030,772
Operating Revenues								
Investment return designated for current operations	3,363,554	-	-	3,363,554	3,597,669	-	-	3,597,669
Subscriptions and fees	1,278,452	-	-	1,278,452	883,959	838	-	884,797
Membership dues	136,630	-	-	136,630	190,986	-	-	190,986
Miscellaneous	255,700	-	-	255,700	393,161	-	-	393,161
Net assets released from restrictions for operations	5,628,513	(5,628,513)	-	-	5,193,327	(5,193,327)	-	-
Total Operating Activities	12,786,063	(1,644,794)	-	11,141,269	12,756,635	(1,659,250)	-	11,097,385
OPERATING EXPENSES								
Program services	8,354,999	-	-	8,354,999	8,286,914	-	-	8,286,914
Management and general	3,035,273	-	-	3,035,273	3,072,054	-	-	3,072,054
Fundraising	1,165,237	-	-	1,165,237	1,272,910	-	-	1,272,910
Total Operating Expenses	12,555,509	-	-	12,555,509	12,631,878	-	-	12,631,878
Change in Net Assets from Operations	230,554	(1,644,794)	-	(1,414,240)	124,757	(1,659,250)	-	(1,534,493)
NON-OPERATING ACTIVITIES								
Permanently restricted contributions	-	-	-	-	-	-	5,000	5,000
Change in value of beneficial interest in perpetual trust	-	-	(11,294)	(11,294)	-	-	(485)	(485)
Valuation adjustment	-	-	(5,000)	(5,000)	-	-	(1,500)	(1,500)
Investment return not designated for current operations	4,096,653	1,436,789	106,776	5,640,218	368,052	1,285,239	73,049	1,726,340
Change in Net Assets	4,327,207	(208,005)	90,482	4,209,684	492,809	(374,011)	76,064	194,862
NET ASSETS								
Beginning of year	44,470,006	20,273,459	11,977,855	76,721,320	43,977,197	20,597,470	11,951,791	76,526,458
Redesignation	-	-	-	-	-	50,000	(50,000)	-
End of year	\$ 48,797,213	\$ 20,065,454	\$ 12,068,337	\$ 80,931,004	\$ 44,470,006	\$ 20,273,459	\$ 11,977,855	\$ 76,721,320

See notes to financial statements

The New York Academy of Medicine

Statement of Functional Expenses Year Ended December 31, 2021

	Program Services					Supporting Services		
	Community Partnerships and Policy Solutions	Evaluation and Research Programs	Library	Other Program Services	Total	Management and General	Fundraising	Total
Salaries and wages	\$ 1,226,289	\$ 819,252	\$ 588,443	\$ 1,367,738	\$ 4,001,722	\$ 1,849,687	\$ 834,213	\$ 6,685,622
Employee benefits and taxes	331,065	219,308	154,421	348,158	1,052,952	445,435	201,000	1,699,387
Professional fees and consultants	237,258	45,287	14,839	83,575	380,959	292,361	3,180	676,500
Program supplies	44,059	11,165	43,257	8,054	106,535	1,572	11,748	119,855
Office expenses	28,670	14,461	11,998	53,680	108,809	61,806	67,895	238,510
Travel, conference and meetings	32,880	27,521	228	5,545	66,174	1,043	1,567	68,784
Contractual services	406,955	58,869	50,339	380,129	896,292	39,388	7,467	943,147
Occupancy and building maintenance	123,644	59,997	88,828	159,267	431,736	60,341	10,940	503,017
Insurance	-	-	-	-	-	166,865	-	166,865
Awards and fellowships	64,996	819	5,657	501,458	572,930	-	-	572,930
Other general and administrative	11,816	4,204	52,918	69,435	138,373	77,012	14,168	229,553
Total Expenses Before Depreciation and Amortization	2,507,632	1,260,883	1,010,928	2,977,039	7,756,482	2,995,510	1,152,178	11,904,170
Depreciation and amortization	193,733	97,413	78,102	229,269	598,517	39,763	13,059	651,339
Total Expenses	\$ 2,701,365	\$ 1,358,296	\$ 1,089,030	\$ 3,206,308	\$ 8,354,999	\$ 3,035,273	\$ 1,165,237	\$ 12,555,509

See notes to financial statements

The New York Academy of Medicine

Statement of Functional Expenses Year Ended December 31, 2020

	Program Services					Supporting Services		
	Community Partnerships and Policy Solutions	Evaluation and Research Programs	Library	Other Program Services	Total	Management and General	Fundraising	Total
Salaries and wages	\$ 606,490	\$ 772,477	\$ 635,594	\$ 2,288,247	\$ 4,302,808	\$ 1,915,298	\$ 905,754	\$ 7,123,860
Employee benefits and taxes	154,049	207,911	160,548	576,058	1,098,566	449,130	203,222	1,750,918
Professional fees and consultants	23,567	19,478	17,114	135,879	196,038	356,833	44,857	597,728
Program supplies	9,531	12,004	45,127	18,977	85,639	15,321	15,841	116,801
Office expenses	8,472	8,402	5,590	14,910	37,374	11,727	17,437	66,538
Travel, conference and meetings	17,999	17,550	2,258	33,031	70,838	1,888	1,301	74,027
Contractual services	180,700	40,066	47,413	372,905	641,084	44,829	6,721	692,634
Occupancy and building maintenance	98,260	64,464	90,448	182,845	436,017	57,068	12,958	506,043
Insurance	-	-	-	-	-	160,003	-	160,003
Awards and fellowships	38,877	-	2,000	525,064	565,941	-	-	565,941
Other general and administrative	<u>2,515</u>	<u>18,435</u>	<u>55,033</u>	<u>90,696</u>	<u>166,679</u>	<u>14,094</u>	<u>49,168</u>	<u>229,941</u>
Total Expenses Before Depreciation and Amortization	1,140,460	1,160,787	1,061,125	4,238,612	7,600,984	3,026,191	1,257,259	11,884,434
Depreciation and amortization	<u>166,862</u>	<u>114,592</u>	<u>96,027</u>	<u>308,449</u>	<u>685,930</u>	<u>45,863</u>	<u>15,651</u>	<u>747,444</u>
Total Expenses	<u>\$ 1,307,322</u>	<u>\$ 1,275,379</u>	<u>\$ 1,157,152</u>	<u>\$ 4,547,061</u>	<u>\$ 8,286,914</u>	<u>\$ 3,072,054</u>	<u>\$ 1,272,910</u>	<u>\$ 12,631,878</u>

See notes to financial statements

The New York Academy of Medicine

Statements of Cash Flows

	Year Ended December 31	
	2021	2020
CASH FLOWS FROM OPERATING ACTIVITIES		
Change in net assets	\$ 4,209,684	\$ 194,862
Adjustments to reconcile change in net assets to net cash from operating activities		
Permanently restricted contributions	-	(5,000)
Depreciation and amortization	651,339	747,444
Bad debt expense	63,174	38,356
Net realized and unrealized gain on investments	(7,430,958)	(4,090,106)
Change in beneficial interest in perpetual trust	11,294	485
Changes in operating assets and liabilities		
Contributions and grants receivable	(324,218)	(117,735)
Accounts receivable	163,737	(124,154)
Prepaid expenses and other assets	(7,249)	75,445
Accounts payable and accrued expenses	61,228	(52,454)
Other payables	(25,382)	(908,071)
Grants payable	143,500	28,500
Deferred income	(153,307)	(34,041)
Net Cash from Operating Activities	(2,637,158)	(4,246,469)
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property and equipment	(374,970)	(393,702)
Purchase of investments	(1,810,053)	(23,193,955)
Proceeds from sales of investments	4,336,696	28,164,639
Net Cash from Investing Activities	2,151,673	4,576,982
CASH FLOWS FROM FINANCING ACTIVITIES		
Perpetual endowment contributions	-	5,000
Net Change in Cash and Cash Equivalents	(485,485)	335,513
CASH AND CASH EQUIVALENTS		
Beginning of year	635,437	299,924
End of year	\$ 149,952	\$ 635,437

See notes to financial statements

The New York Academy of Medicine

Notes to Financial Statements
December 31, 2021 and 2020

1. Organization and Tax Status

The New York Academy of Medicine (“NYAM”) tackles the barriers that prevent every individual from living a healthy life. NYAM generates the knowledge needed to change the systems that prevent people from accessing what they need to be healthy such as safe and affordable housing, healthy food, healthcare and more. Through its high-profile programming for the general public, focused symposia for health professionals, and its base of dedicated Fellows and Members, NYAM engages the minds and hearts of those who also value advancing health equity to maximize health for all.

NYAM is exempt from federal income taxes pursuant to Section 501(c) (3) of the U.S. Internal Revenue Code and from state and local taxes under comparable laws.

2. Summary of Significant Accounting Policies

Basis of Accounting and Use of Estimates

The accompanying financial statements of NYAM have been prepared using the accrual basis of accounting and conform to accounting principles generally accepted in the United States of America as (“U.S. GAAP”), as applicable to not-for-profit organizations.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

NYAM considers highly liquid financial instruments purchased with a maturity of three months or less to be cash equivalents, with the exception of cash and cash equivalents held in the investment portfolio.

Investment Valuation and Income Recognition

NYAM's investments consist of (i) cash and cash equivalents held for investments, (ii) fully benefit responsive contracts, (iii) domestic and international equity securities, (iv) fixed-income securities, (v) equity mutual funds, (vi) CREF variable annuity accounts, (vii) a real estate pooled separate account, and (viii) alternative investments consisting of limited partnerships invested in private equity securities, flexible capital, hedge funds and real asset funds. The fully benefit responsive contracts are unallocated contracts and are stated at contract value. Contract value equals the accumulated cash contributions, interest credited to the contracts, and transfers in (if any), less any withdrawals and transfers out (if any). The contract value, which is derived from a discounted cash flow analysis and other factors, approximates fair value. Domestic and international equity securities, fixed-income securities, equity mutual funds, CREF variable annuity accounts and the real estate pooled separate account are reported at their fair values at year-end based on market quotations. The alternative investments are reported at their fair values at year-end, based upon the valuation of the underlying assets as provided by the various investment managers.

The New York Academy of Medicine

Notes to Financial Statements
December 31, 2021 and 2020

2. Summary of Significant Accounting Policies *(continued)*

Investment Valuation and Income Recognition (continued)

The methods and procedures used to value these alternative investments may include, but are not limited to, (i) performing comparisons with prices of comparable or similar securities; (ii) obtaining valuation-related information from issuers; and (iii) obtaining such other analytical data and indications of value as may be available from investment managers and other sources. However, because of the inherent uncertainty of the valuation process, the estimated fair values for the aforementioned securities and interests may differ from the values that would have been used had a ready market for the investments existed, and those differences could be material.

NYAM uses Net Asset Value (“NAV”) or its equivalent as a practical expedient to measure the fair values of certain investments. This applies to investments (a) which do not have a readily determinable fair value and (b) the financial statements, which were prepared by the respective investment managers, consistent with the measurement principles of an investment company or that have the attributes of an investment company.

NYAM's investments in limited partnerships are valued based on the valuation policies and procedures of the general partners. Each general partner performs oversight of the underlying managers' material positions both on an investment level and from a risk perspective. The general partner is responsible for ensuring the investments are valued according to the policies and procedures adopted by the partnership. NYAM places reliance upon those procedures and records these investments at fair value as determined by the general partner.

NYAM's investments are subject to various risks, such as interest-rate, market, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of those securities could occur in the near term and that such changes could materially affect the amounts reported in the accompanying financial statements.

NYAM commingles its investments within a common investment pool to achieve a maximum return. Investment income, including realized and unrealized gains and losses, is allocated on a pro-rata basis to each of the participating restricted funds. Interest and dividend income, as well as realized and unrealized gains and losses, are reported as net assets with or without restrictions, in accordance with the donors' intentions.

Donated securities are recorded at their fair values at the dates of donation. It is NYAM's policy to sell the donated securities immediately upon receipt.

The New York Academy of Medicine

Notes to Financial Statements
December 31, 2021 and 2020

2. Summary of Significant Accounting Policies (*continued*)

Fair Value Measurements

NYAM follows U.S. GAAP guidance on Fair Value Measurements which defines fair value and establishes a fair value hierarchy organized into three levels based upon the input assumptions used in pricing assets. Level 1 inputs have the highest reliability and are related to assets with unadjusted quoted prices in active markets. Level 2 inputs relate to assets with other than quoted prices in active markets which may include quoted prices for similar assets or liabilities or other inputs which can be corroborated by observable market data. Level 3 inputs are unobservable inputs and are used to the extent that observable inputs do not exist.

U.S. GAAP guidance provides for the use of NAV as a “Practical Expedient” for estimating fair value of alternative investments. NAV reported by each alternative investment fund is used as a practical expedient to estimate the fair value of NYAM’s interest therein.

Pursuant to U.S. GAAP guidance, alternative investments where fair value is measured using NAV are not categorized within the fair value hierarchy.

Investments Risks and Uncertainties

Alternative investments consist of non-traditional, not readily marketable investments, some of which may be structured as offshore limited partnerships, venture capital funds, hedge funds, private equity funds and common trust funds. The underlying investments of such funds, whether invested in stock or other securities, are generally not currently traded in a public market and typically are subject to restrictions on resale. Values determined by investment managers and general partners of underlying securities that are thinly traded or not traded in an active market may be based on historical cost, appraisals, a review of the investees’ financial results, financial condition and prospects, together with comparisons to similar companies for which quoted market prices are available or other estimates that require varying degrees of judgment.

Because of the inherent uncertainty of valuations, the estimated fair values may differ significantly from the values that would have been used had a ready market for such investments existed or had such investments been liquidated, and those differences could be material.

Restricted Investments

Restricted investments relate to NYAM’s deferred compensation plan and include marketable securities recorded at fair value and fully benefit responsive contracts recorded at contract value.

The New York Academy of Medicine

Notes to Financial Statements
December 31, 2021 and 2020

2. Summary of Significant Accounting Policies (*continued*)

Property and Equipment

NYAM's property and equipment are stated at their costs at the dates of acquisition. NYAM capitalizes all property and equipment expenditures or additions in excess of \$5,000. Depreciation is calculated using the straight-line method over the estimated useful lives of (i) building, building improvements and land improvements, which range from 7 to 40 years; (ii) library books and publications, which range from 20 to 40 years; and (iii) furniture and equipment, which range from 5 to 15 years. Land is not depreciated. Minor costs for repairs and maintenance are expensed as incurred.

Management evaluates the recoverability of the investment in long-lived assets on an on-going basis and recognizes any impairment in the year of determination. Long-lived assets were tested for impairment as of December 31, 2021 and 2020, and in the opinion of management, there were no impairments. It is reasonably possible that relevant conditions could change in the near term and necessitate a change in management's estimate of the recoverability of these assets.

Collection

NYAM has a collection of various purchased and donated materials, including books and artifacts. This collection is maintained by NYAM under curatorial care and is held for research, education and public exhibition in furtherance of public service. In accordance with not-for-profit industry practice, the costs and values of the items in the collection have not been capitalized and are not reported in the accompanying statements of financial position.

Accrued Vacation

Employees accrue vacation monthly with a provision for carryover of up to five unused days at the end of each calendar year, which must be taken by June 30 of the following year. Accrued vacation is included in accounts payable and accrued expenses in the accompanying financial statements and represents NYAM's obligation for the cost of unused employee vacation time that would be owed if employees were to leave NYAM's employment. As of December 31, 2021 and 2020, accrued vacation obligations were approximately \$102,000 and \$161,000 and are included in accounts payable and accrued expenses.

Deferred Income

Payments related to the rental of conference center space received in advance are recorded as deferred income and are recognized when earned in the subsequent year.

The New York Academy of Medicine

Notes to Financial Statements
December 31, 2021 and 2020

2. Summary of Significant Accounting Policies (*continued*)

Grants Payable

NYAM has certain awards and fellowship programs that are funded from endowed gifts, as well as from individual contributions. These program awards are determined and approved by applicable program committees. NYAM reports the full award commitment upon approval by the funding committee.

Net Assets

NYAM's net assets, as well as its revenues, expenses, gains and losses, are classified based on the existence or absence of donor-imposed restrictions. Accordingly, the net assets of NYAM and changes therein are classified and reported as follows:

Without donor restrictions - those resources that are not subject to donor-imposed restrictions and are available for the support of operations.

With donor restrictions - represent amounts restricted by donors to be used for specific activities or at some future date, or which require NYAM to maintain in perpetuity, including funds that are subject to restrictions or gift instruments requiring that the principal be invested in perpetuity and the income be used for specific or general purposes. Income and gains earned on endowment fund investments are available to be used in the "without donor restrictions" or "with donor restrictions" net asset classes based upon stipulations by the donors.

Contributions and Grants

Contributions and grants to NYAM are recognized as revenue upon the receipt of cash, securities, or unconditional pledges. Unconditional promises to give to NYAM that are expected to be collected in future years are recorded at the present value of their estimated future cash flows, discounted using risk-free interest rates applicable to the years in which payments are expected to be received. Contributions received with no explicit donor-restrictions are considered to be available for the general purposes of NYAM. Conditional promises to give are not included until such conditions are substantially met.

Management provides an allowance for uncollectible amounts through a provision for bad debt expense based on its assessment of the current status of individual accounts. Balances that are still outstanding, after management has used all reasonable collection efforts, are charged to the allowance with a corresponding credit to contributions and grants receivable. The allowance for doubtful accounts was \$63,670 and \$26,662 as of December 31, 2021 and 2020.

The New York Academy of Medicine

Notes to Financial Statements
December 31, 2021 and 2020

2. Summary of Significant Accounting Policies *(continued)*

Contributions and Grants (continued)

NYAM reports contributions and grants in net assets with donor restrictions if they are received with donor stipulations or time considerations as to their use. When a donor's restriction is met, that is, when a stipulated time restriction ends or the purpose of the restriction is accomplished, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the accompanying statements of activities as net assets released from restrictions.

Subscriptions and Fees and Membership Dues

Subscriptions and fees consist of fees for (i) library services, (ii) the conference center facility, (iii) program registration fees, (iv) program sponsorship fees, and (v) lease income. The income is recognized when services are rendered. Membership dues are recorded as income in the applicable membership period as the services or goods are provided to the members.

Measure of Operations

NYAM includes in its definition of operations all revenues and expenses that are an integral part of its programs and supporting activities, including an authorized investment income allocation and all contributions except for those that are restricted for capital expenditures or to be held in perpetuity by donors. Investment income, including net realized and unrealized gains and losses, earned in excess of (or less than) NYAM's aggregate authorized spending amount, contributions for capital expenditures, change in value of beneficial interest in perpetual trust and perpetual endowment contributions are recognized as non-operating activities.

Functional Allocation of Expenses

The costs of providing the various programs and supporting services have been summarized on a functional basis in the accompanying statements of activities. Accordingly, certain expenses have been allocated among the programs and supporting services in reasonable ratios determined by management. Specific expenses that are readily identifiable to a single program or activity are charged directly to that function. For example, programs include research, evaluation and policy, community partnerships, the library and fellows. Certain expenses attributable to more than one program or supporting function have been allocated among programs, management and general and fundraising. These expenses include salaries and wages, professional fees and consultants, office expenses, travel conference and meetings, and occupancy and building maintenance, which are allocated based on estimates of time and effort and building space occupied.

The New York Academy of Medicine

Notes to Financial Statements
December 31, 2021 and 2020

2. Summary of Significant Accounting Policies (*continued*)

Accounting for Uncertainty in Income Taxes

NYAM is subject to the provisions of the Financial Accounting Standards Board's Accounting Standards Codification ("ASC") Topic 740, *Income Taxes*, as it relates to accounting and reporting for uncertainty in income taxes. For NYAM, ASC Topic 740 is potentially applicable to the incurrence of unrelated business income ("UBI"), attributable to certain alternative investments, conference center events and commissions, and sponsorship fees not related to NYAM's mission. Nonetheless, because of NYAM's general tax-exempt status, management believes that ASC Topic 740 has not had, and is not expected to have, a material impact on NYAM's financial statements. NYAM is no longer subject to examinations by the applicable taxing jurisdictions for periods prior to 2018.

Redesignation

In 2020, management reviewed a fund previously designated as a perpetual endowment with the donor. The donor approved conversion of the endowment fund to a restricted gift fund. Based upon that review and approval, the fund was re-designated as a purpose restricted fund with approval by the Board of Trustees.

Subsequent Events

Management has evaluated subsequent events for disclosure and/or recognition in the financial statements through the date the financial statements were available to be issued, which date is May 23, 2022.

3. Concentrations of Credit Risk

Certain financial instruments potentially subject NYAM to concentrations of credit risk. These financial instruments consist primarily of cash and cash equivalents. NYAM places its cash and investments with creditworthy, high-quality financial institutions. A portion of such cash and investments are not insured by the FDIC or SIPC. Management believes there is a very low risk of loss due to the failure of these institutions.

At December 31, 2021, NYAM had contributions and grants receivable due from one New York City agency and one university totaling \$380,385. At December 31, 2020, NYAM had contributions and grants receivable due from one federal agency, one foundation, one university, and one individual totaling \$781,842. These amounts represented approximately 24% and 60% of the total outstanding contributions and grants as of December 31, 2021 and 2020. For the year ended December 31, 2021, NYAM received approximately 16% of total grants and contributions from one foundation.

The New York Academy of Medicine

Notes to Financial Statements December 31, 2021 and 2020

4. Investments

The following summarizes the unrestricted investments held by NYAM as of December 31:

	2021		2020	
	Cost	Fair Value	Cost	Fair Value
Cash and cash equivalents	\$ 75,000	\$ 75,000	\$ -	\$ -
Domestic and international equity securities	26,782,646	48,505,489	27,811,051	44,518,274
Fixed-income mutual funds	19,214,638	18,639,788	18,678,003	18,871,736
Flexible capital and hedge funds	16,497	83,675	28,990	84,044
Real estate funds	3,853,488	5,461,952	3,989,992	4,291,977
Private equity securities	482,947	349,785	482,947	445,343
	<u>\$ 50,425,216</u>	<u>\$ 73,115,689</u>	<u>\$ 50,990,983</u>	<u>\$ 68,211,374</u>

Restricted investments consist of the following at December 31:

	2021		2020	
	Cost	Fair Value	Cost	Fair Value
Investments, at Fair Value				
Equity mutual funds	\$ 998,116	\$ 1,082,330	\$ 664,714	\$ 788,145
CREF variable annuity accounts	148,158	173,627	179,219	230,791
Pooled separate account - real estate	34,054	54,278	35,410	48,756
	1,180,328	1,310,235	879,343	1,067,692
Investments, at contract value	117,550	134,954	159,470	179,265
Total Restricted Investments	<u>\$ 1,297,878</u>	<u>\$ 1,445,189</u>	<u>\$ 1,038,813</u>	<u>\$ 1,246,957</u>

The investment return from investments and their classifications in the accompanying statements of activities is as follows for the years ended December 31:

	2021			
	Without Donor Restrictions	Time or Purpose Restricted	Investments Held in Perpetuity	Total
Dividends and interest	\$ 1,355,763	\$ 274,319	\$ -	\$ 1,630,082
Realized gains	1,634,499	326,377	-	1,960,876
Unrealized gains	4,517,637	845,669	106,776	5,470,082
Less: Custody and administrative fees	(47,692)	(9,576)	-	(57,268)
Investment Return	7,460,207	1,436,789	106,776	9,003,772
Less: Investment return designated for current operations (spending rate and special funding)	(3,363,554)	-	-	(3,363,554)
Investment return not designated for current operations	<u>\$ 4,096,653</u>	<u>\$ 1,436,789</u>	<u>\$ 106,776</u>	<u>\$ 5,640,218</u>

The New York Academy of Medicine

Notes to Financial Statements December 31, 2021 and 2020

4. Investments (continued)

	2020			
	Without Donor Restrictions	Time or Purpose Restricted	Investments Held in Perpetuity	Total
	Dividends and interest	\$ 1,043,334	\$ 244,822	\$ -
Realized gains	593,046	126,263	-	719,309
Unrealized gains	2,373,058	924,690	73,049	3,370,797
Less: Custody and administrative fees	<u>(43,717)</u>	<u>(10,536)</u>	<u>-</u>	<u>(54,253)</u>
Investment Return	3,965,721	1,285,239	73,049	5,324,009
Less: Investment return designated for current operations (spending rate and special funding)	<u>(3,597,669)</u>	<u>-</u>	<u>-</u>	<u>(3,597,669)</u>
Investment return not designated for current operations	<u>\$ 368,052</u>	<u>\$ 1,285,239</u>	<u>\$ 73,049</u>	<u>\$ 1,726,340</u>

Included within the custody and administrative fees disclosed above are those specific fees charged by NYAM's investment managers and advisors; however, fees that are embedded in various other mutual fund accounts and transactions are not reflected in that amount.

5. Fair Value Measurements

The following are the classes and major categories of assets measured at fair value on a recurring basis, grouped by the fair value hierarchy, as of December 31:

	2021				
	Amounts within Fair Value Hierarchy			Investments Valued Using	Total
	Level 1	Level 2	Level 3	NAV (*)	
Domestic and international equity securities	\$ 48,505,489	\$ -	\$ -	\$ -	\$ 48,505,489
Fixed-income mutual funds	18,639,788	-	-	-	18,639,788
Equity mutual funds	1,082,330	-	-	-	1,082,330
CREF variable annuity accounts	-	173,627	-	-	173,627
Pooled separate account - real estate	-	54,278	-	-	54,278
Flexible capital and hedge funds	-	-	-	83,675	83,675
Real estate funds	5,319,365	-	-	142,587	5,461,952
Private equity securities	<u>-</u>	<u>-</u>	<u>-</u>	<u>349,785</u>	<u>349,785</u>
Total Investments at Fair Value	73,546,972	227,905	-	576,047	74,350,924
Beneficial interest in perpetual trust	<u>-</u>	<u>-</u>	<u>160,678</u>	<u>-</u>	<u>160,678</u>
Total Assets at Fair Value	<u>\$ 73,546,972</u>	<u>\$ 227,905</u>	<u>\$ 160,678</u>	<u>\$ 576,047</u>	74,511,602
Short-term cash investments, at cost					75,000
Investments, at contract value					134,954
Total Investments					<u>\$ 74,721,556</u>

The New York Academy of Medicine

Notes to Financial Statements
December 31, 2021 and 2020

5. Fair Value Measurements *(continued)*

	2020				
	Amounts within Fair Value Hierarchy			Investments Valued Using	Total
	Level 1	Level 2	Level 3	NAV (*)	
Domestic and international equity securities	\$ 44,518,274	\$ -	\$ -	\$ -	\$ 44,518,274
Fixed-income mutual funds	18,871,736	-	-	-	18,871,736
Equity mutual funds	788,145	-	-	-	788,145
CREF variable annuity accounts	-	230,791	-	-	230,791
Pooled separate account - real estate	-	48,756	-	-	48,756
Flexible capital and hedge funds	-	-	-	84,044	84,044
Real estate funds	4,014,492	-	-	277,485	4,291,977
Private equity securities	-	-	-	445,343	445,343
Total Investments at Fair Value	<u>68,192,647</u>	<u>279,547</u>	-	806,872	<u>69,279,066</u>
Beneficial interest in perpetual trust	-	-	171,972	-	171,972
Total Assets at Fair Value	<u>\$ 68,192,647</u>	<u>\$ 279,547</u>	<u>\$ 171,972</u>	<u>\$ 806,872</u>	69,451,038
Investments, at contract value					179,265
Total Investments					<u>\$ 69,630,303</u>

(*) As discussed in Note 2, investments that are measured using the practical expedient are not classified within the fair value hierarchy.

Changes from the beginning to ending balances for investments measured at fair value using significant unobservable inputs (Level 3) consist only of changes in beneficial interest in perpetual trust reported on the accompanying statements of activities totaling (\$11,294) and (\$485) for the years ended December 31, 2021 and 2020.

Information regarding alternative investments measured at fair value using the practical expedient at December 31, 2021 is as follows:

	Fair Value	Unfunded Commitments	Redemption Frequency	Redemption Notice Period
Flexible capital and hedge funds (see "a" below)	\$ 83,675	\$ -	Annually	45 days
Real asset funds (limited partnerships) (see "b" below)	142,587	127,137	N/A*	N/A*
Private equity securities (see "c" below)	349,785	497,110	N/A*	N/A*
	<u>\$ 576,047</u>	<u>\$ 624,247</u>		

* These investments are illiquid investments.

- a. NYAM's investment at year-end was primarily in absolute return oriented strategies which allocates to long/short equity, long/short credit, and event-driven investments. Event driven investments focus on unlocking value through event catalysts such as company mergers and distressed situations. The investment can be redeemed annually with 45 days of notice.

The New York Academy of Medicine

Notes to Financial Statements
December 31, 2021 and 2020

5. Fair Value Measurements *(continued)*

- b. NYAM invests as a limited partner in funds, which in turn invest in private companies and private commercial properties that are not traded on an exchange. Strategies may include investments in private commercial real estate, and private natural resource and commodity related firms. NYAM's investments at year-end were in a private real estate fund and a multi-strategy private real asset fund. These investments are illiquid and currently in liquidation. Proceeds will be paid out over the coming years.
- c. NYAM's investments at year-end were as a limited partner in funds, which in turn invest in private companies that are not traded on an exchange. Investment strategies in this category include, leveraged buyout, venture capital, and opportunistic/distressed. NYAM's investments at year-end were primarily in opportunistic/distressed and secondary funds. These are long-term investments that cannot be redeemed at the discretion of NYAM. Instead, distributions are received through the liquidation of the underlying assets of the funds. Management has estimated that the underlying assets of the funds will be liquidated over 10 to 12 years.

6. Contributions and Grants Receivable

At December 31, contributions and grants receivable are estimated to be received as follows:

	2021	2020
Due less than one year	\$ 1,617,527	\$ 1,219,734
Due between one and two years	-	100,000
	<u>1,617,527</u>	<u>1,319,734</u>
Less discount to present value	-	(259)
Less allowance for doubtful accounts	<u>(63,670)</u>	<u>(26,662)</u>
Present value of contributions receivable	<u>\$ 1,553,857</u>	<u>\$ 1,292,813</u>

A present value discount using a rate of 0.13% for 2020 has been calculated using discount factors that approximate the risk and expected timing of future contribution payments.

The New York Academy of Medicine

Notes to Financial Statements
December 31, 2021 and 2020

7. Property and Equipment

Property and equipment at December 31 consisted of the following:

	<u>2021</u>	<u>2020</u>
Land and land improvements	\$ 284,261	\$ 284,261
Building and building improvements	13,815,672	13,805,470
Library books and publications	2,651,348	2,651,348
Furniture and equipment	1,038,029	1,038,029
Construction-in-process	<u>614,639</u>	<u>249,871</u>
	18,403,949	18,028,979
Less accumulated depreciation and amortization	<u>(11,192,178)</u>	<u>(10,540,839)</u>
	<u>\$ 7,211,771</u>	<u>\$ 7,488,140</u>

During 2021 and 2020, approximately \$0 and \$150,000 of fully depreciated library books and publications, building improvements and furniture and equipment were removed from the property and equipment balances.

8. Beneficial Interest in Perpetual Trust

NYAM is the remainder beneficiary of a perpetual trust arrangement. The fair value of the trust as of December 31, 2021 and 2020 was determined by its trustee. NYAM receives a quarterly distribution of income from the trust.

9. PPP Loan Payable

On April 6, 2020, NYAM received loan proceeds in the amount of \$1,568,262 under the Paycheck Protection Program (the "PPP"). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act"), provides for loans to qualifying entities for amounts up to 2.5 times their 2019 average monthly payroll expenses of the qualifying entity.

On February 9, 2021, NYAM received loan proceeds in the amount of \$1,442,947 under Second Draw provisions of the PPP as authorized by the Economic Aid to Hard-Hit Small Businesses, Nonprofits, and Venues Act (the "Economic Aid Act"). The Second Draw provisions of the Economic Aid Act provides for loans to qualifying entities for amounts to 2.5 times their 2019 and 2020 average monthly payroll expenses.

The New York Academy of Medicine

Notes to Financial Statements
December 31, 2021 and 2020

9. PPP Loan Payable (*continued*)

NYAM has elected to report the PPP loan proceeds as conditional grants under requirements contained in ASU 2018-08, "Clarifying the Scope and Accounting Guidance for Contributions Received and Contributions Made." Accordingly, NYAM recognizes income as the conditions of the PPP are met. For the years ended December 31, 2021 and 2020, NYAM recognized the full amount of the proceeds from the PPP loans as PPP loan forgiveness in the statements of activities. On May 11, 2021, NYAM was approved for the loan forgiveness by the SBA for the First Draw PPP loan in the amount of \$1,568,262. On April 8, 2022, NYAM received notification of forgiveness for the entire Second Draw PPP loan in the amount of \$1,442,947.

10. Net Assets with Donor Restrictions

At December 31, net assets with donor restrictions consisted of the following:

	2021	2020
Time or Purpose Restricted:		
Lectures and Awards Programs	\$ 12,289,707	\$ 13,025,610
Library	1,748,685	1,918,291
Community Programs and Policy Solutions	1,557,606	1,702,769
Center for Cognitive Studies in Medicine	316,577	278,616
Population Health Programs	-	13,760
Center for Health Innovation	-	-
Center for Evaluation and Applied Research	199,615	282,817
Advocates for Health Equity	25,000	-
Other programs	3,928,264	3,051,596
	20,065,454	20,273,459
Held In Perpetuity		
Beneficial interest in perpetual trust	160,678	171,972
Endowment funds	11,907,659	11,805,883
	\$ 32,133,791	\$ 32,251,314

The New York Academy of Medicine

Notes to Financial Statements
December 31, 2021 and 2020

10. Net Assets with Donor Restrictions *(continued)*

Net assets with donor restrictions released from restrictions consisted of the following for the years ended December 31:

	2021	2020
Lectures and Awards Programs	\$ 1,094,899	\$ 1,477,576
Library	492,437	508,627
Community Programs and Policy Solutions	2,290,204	1,038,273
Center for Cognitive Studies in Medicine	713,190	625,595
Population Health Programs	13,760	1,040
Center for Health Innovation	-	422,478
Center for Evaluation and Applied Research	1,019,707	1,116,170
Other programs	4,316	3,568
	\$ 5,628,513	\$ 5,193,327

At December 31, investments held in perpetuity consisted of the following:

	2021	2020
Lectures and Awards Program	\$ 5,541,605	\$ 5,541,605
Library	5,764,879	5,722,786
Support of General Operations	761,853	713,464
	\$ 12,068,337	\$ 11,977,855

11. Endowment

The endowment consists of 43 individual donor-restricted funds that have been established for a variety of purposes. NYAM does not have any funds designated by the Board of Trustees to function as an endowment.

Return Objectives and Risk Parameters

NYAM has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment, while seeking to maintain the purchasing power of the endowment assets. Endowment assets include those assets of donor-restricted funds that NYAM must hold in perpetuity. Under this policy, as approved by the Board of Trustees, the endowment assets are invested in a manner that is intended to produce an inflation adjusted real return over time that enables these programs to be sustained.

The New York Academy of Medicine

Notes to Financial Statements
December 31, 2021 and 2020

11. Endowment (*continued*)

Strategies Employed for Achieving Objectives

To satisfy its long-term, rate-of-return objectives, NYAM relies on a total-return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). At present, endowment assets are allocated as follows:

- Cash
- Equity securities
- Fixed-income securities
- Flexible capital and hedge funds
- Real assets
- Private equity

Spending Policy and How the Investment Objectives Relate to the Spending Policy

NYAM's spending policy provides that NYAM will generally spend up to 5% of the value of restricted funds each year. The overall spending policy goal is 5% to 6% of a three-year rolling average of the market value of the portfolio. The three-year average market value is calculated based on the prior three years' values.

Interpretation of Relevant Law

In classifying endowment funds for financial statement purposes as either net assets with donor restrictions or net assets without donor restrictions, the Board of Trustees looks to the explicit direction of the donor and the New York Prudent Management of Investment Funds Act (NYPMIFA).

The Board of Trustees of NYAM has interpreted NYPMIFA as allowing NYAM to appropriate for expenditure or accumulate so much of an endowment fund as NYAM determines is prudent for the uses, benefits, purposes and duration for which the endowment fund is established, subject to the intent of the donor as expressed in the gift instrument. Unless stated otherwise in the gift instrument, the assets in an endowment fund shall be donor-restricted assets until appropriated for expenditure by the Board of Trustees. NYPMIFA is applicable to all of NYAM's institutional funds. NYAM adheres to NYPMIFA's requirements.

The New York Academy of Medicine

Notes to Financial Statements
December 31, 2021 and 2020

11. Endowment *(continued)*

Changes in endowment net assets for the years ended December 31:

	2021		
	Time or Purpose Restricted	Investments Held in Perpetuity	Total
Endowment funds, beginning of year	\$ 11,577,933	\$ 11,805,883	\$ 23,383,816
Valuation adjustment	-	(5,000)	(5,000)
Investment return	1,436,789	106,776	1,543,565
Appropriation of endowment assets for expenditures	<u>(678,063)</u>	-	<u>(678,063)</u>
Total endowment net assets, end of year	<u>\$ 12,336,659</u>	<u>\$ 11,907,659</u>	<u>\$ 24,244,318</u>
Comprised of the following:			
Donor-restricted endowment funds	<u>\$ 12,336,659</u>	<u>\$ 11,907,659</u>	<u>\$ 24,244,318</u>
	2020		
	Time or Purpose Restricted	Investments Held in Perpetuity	Total
Endowment funds, beginning of year	\$ 11,082,655	\$ 11,779,334	\$ 22,861,989
Contributions	-	5,000	5,000
Valuation adjustment	-	(1,500)	(1,500)
Investment return	1,285,239	73,049	1,358,288
Contributions previously designated as endowment redesignated as time or purpose restricted	-	(50,000)	(50,000)
Appropriation of endowment assets for expenditures	<u>(789,961)</u>	-	<u>(789,961)</u>
Total endowment net assets, end of year	<u>\$ 11,577,933</u>	<u>\$ 11,805,883</u>	<u>\$ 23,383,816</u>
Comprised of the following:			
Donor-restricted endowment funds	<u>\$ 11,577,933</u>	<u>\$ 11,805,883</u>	<u>\$ 23,383,816</u>

Funds with Deficiencies

As a result of unfavorable market fluctuations, from time-to-time the fair value of assets associated with individual donor-restricted endowment funds may decline below the historic dollar value of the donor's original perpetual endowment contribution. As of December 31, 2021 and 2020, there were no funds with deficiencies.

The New York Academy of Medicine

Notes to Financial Statements
December 31, 2021 and 2020

12. Liquidity and Availability of Financial Assets

The following reflect NYAM's financial assets as of December 31, reduced by amounts not available for general use within one year of that date because of contractual or donor-imposed restrictions or internal designations.

	<u>2021</u>	<u>2020</u>
Financial Assets:		
Cash and cash equivalents	\$ 149,952	\$ 635,437
Contributions and grants receivable, net	1,553,857	1,292,813
Accounts receivable	80,752	244,489
Investments	73,115,689	68,211,374
Beneficial interest in perpetual trust	<u>160,678</u>	<u>171,972</u>
Total Financial Assets	<u>75,060,928</u>	<u>70,556,085</u>
Less amounts not available to be used within one year:		
Restricted by donor with time or purpose restrictions	20,065,454	20,273,459
Investments held in perpetuity	12,068,337	11,977,855
Less net assets with purpose or time restrictions to be met in less than one year	<u>(4,626,037)</u>	<u>(4,447,251)</u>
	<u>27,507,754</u>	<u>27,804,063</u>
Financial assets available to meet general expenditures over the next twelve months	<u>\$ 47,553,174</u>	<u>\$ 42,752,022</u>

At the end of each year management prepares and submits an operating budget and a capital budget for the following year to the Board of Trustees for approval. Based on the Board-approved budget, management develops monthly cash flow needs and shares them with NYAM's investment manager. Because of variability in receipt of grant, contract and donation funds throughout the year, funds are not necessarily withdrawn from the investment portfolio each month. Rather funds are withdrawn as needed for both donor restricted and non-donor restricted operations.

13. Employee Benefit Plans

Section 403(b) Plan

NYAM has a Section 403(b), defined-contribution employee-benefit plan, covering all of its full-time salaried employees. The plan is funded through individual annuity contracts that NYAM maintains with the Teachers Insurance and Annuity Association - College Retirement Equities Fund. Under the plan, a fixed percentage (3.0% for both 2021 and 2020) of an employee's annual compensation is contributed by NYAM, up to a maximum of \$7,950 for 2021 and 2020.

The accumulated funds are 100% vested with the participants. The retirement expense for 2021 and 2020 was \$367,559 and \$414,508.

The New York Academy of Medicine

Notes to Financial Statements
December 31, 2021 and 2020

13. Employee Benefit Plans (*continued*)

Deferred Compensation Plan

NYAM has a Section 457(b) deferred-compensation plan which is available to key employees. All amounts deferred under the plan and all income attributable to such amounts, remain (until paid or made available to the participant or beneficiary) solely the property of NYAM (without being restricted to the provision of benefits under the plan), subject only to the claims of NYAM's general creditors. During 2021 and 2020, there were 6 and 5 employees participating in this plan, of which 5 and 4 employees' contributions were funded by NYAM, for a total of approximately \$76,000 and \$78,000. The plan is maintained with the Teachers Insurance and Annuity Association - College Retirement Equities Fund and reported in restricted investments on the statement of financial position. NYAM records a corresponding liability for the deferred compensation obligation, totaling \$1,445,189 and \$1,246,957 at December 31, 2021 and 2020 which represents the cumulative amount of the contributions to the 457(b) plan, as well accumulated earnings and losses since the 457(b) plan's inception.

14. Commitments

Effective February 2014, NYAM entered into a five-year, non-exclusive Affiliation Agreement with the Icahn School of Medicine at Mount Sinai, New York City, (Icahn School) for the purpose of collaborating on research, education and health-policy activities. In addition, as of November 2014, the Icahn School entered into a five-year lease agreement with NYAM for the rental of two office spaces from NYAM. Effective June 2020, the Icahn School entered into a one-year lease extension agreement with NYAM for the same space and purpose as the lease described above. The lease agreement expired in December 2021. NYAM also leases other office space to another not-for-profit organization that expired in 2020.

Effective January 1 2022, the Icahn School entered into a one-year lease extension agreement with NYAM for the same space and purpose as the lease described above. The lease agreement will expire in December 2022. The required annual payments under the leases total \$419,523 for 2022.

Total rental income was \$412,668 and \$402,937 in 2021 and 2020.

Annual lease expense was \$8,154 and \$8,386 in 2021 and 2020.

In the normal course of business, NYAM enters into various contracts for professional and other services, which are typically renewable on a year-to-year basis.

The New York Academy of Medicine

Notes to Financial Statements
December 31, 2021 and 2020

15. COVID-19

The full duration and extent of the COVID-19 pandemic, related business and travel restrictions and changes to behavior intended to reduce its spread are uncertain as of the date these financial statements were available for issuance. Therefore, the full extent of any adverse impact on the results of operations, financial position and cash flows in fiscal 2022 cannot be reasonably estimated at this time.

The COVID-19 pandemic has resulted in volatility in the global financial markets. As a result, NYAM's investments may have incurred a fluctuation in their fair value. Because the value of NYAM's investments has and will fluctuate in response to changing market conditions, the amount of losses, if any, that will be recognized in subsequent periods, cannot be determined.

* * * * *